A follow-on, Two-year Open-label Extension Study of Ganaxolone as add-on Therapy in Adult Patients With Drug-resistant Partial-onset Seizures

Trial Profile

A follow-on, Two-year Open-label Extension Study of Ganaxolone as add-on Therapy in Adult Patients With Drug-resistant Partial-onset Seizures

Discontinued
Phase of Trial: Phase III

Latest Information Update: 11 Jan 2017

At a glance

  • Drugs Ganaxolone (Primary)
  • Indications Partial epilepsies
  • Focus Adverse reactions
  • Sponsors Marinus Pharmaceuticals
  • Most Recent Events

    • 06 Jan 2017 Status changed from recruiting to discontinued as Ganaxolone missed its primary endpoint in the double-blind portion of the 1042-0603 study.
    • 13 Aug 2015 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top